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experimental study using a plasma
expander in a murine model
Stefan M. Zimmermann*, Lukas W. Schwitter, Max J. Scheyerer, Thorsten Jentzsch, Hans-Peter Simmen
and Clément M. L. Werner
Abstract
Background: Heterotopic ossification (HO) is a frequent complication following orthopedic and trauma surgery.
It often leads to substantial morbidity as many affected patients suffer from pain and joint contractures. Current
prophylactic measures include nonsteroidal anti-inflammatory drugs (NSAID) and local radiation. However, several
disadvantages such as delayed fracture healing and impaired ossification have been reported. For this reason, a
novel approach for prevention of HO was searched for.
We hypothesized that systemic administration of hydroxyethyl starch (HES), a substance known to influence
microcirculation, would reduce formation of HO in a murine model.
Methods: A pre-established murine model was used where HO has been shown to develop following Achilles tendon
tenotomy. Twenty CD1 mice were randomly assigned to a control (n = 10) or treatment group (n = 10). The
treatment group received two intravenous HES injections perioperatively, while the control group underwent
tenotomy only. After ten weeks, the mice were euthanized and micro CT scans of the hind limbs were
performed. HO was manually identified and quantitatively assessed. A Wilcoxon rank sum test was used for
comparison of both groups.
Results: The mean heterotopic bone volume in the control group was significantly larger compared to the
HES group (2.276 mm3 vs. 0.271 mm3, p = 0.005). A reduction of mean ectopic bone volume of 88 % was
found following administration of HES.
Conclusion: A substantial reduction of HO formation was found following perioperative short-term administration
of HES. This work represents a preliminary study, necessitating further studies before drawing ultimate conclusions.
However, this simple addition to current prophylactic measures might lead to a more effective prevention of HO in
the future.
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Background
Heterotopic ossification (HO) is defined as the presence
of lamellar bone in soft tissues, where bone does not
normally occur [1]. It is typically found following fractures
and dislocations, burns, as well as operative procedures.
Apart from some genetic origins, it is most commonly
observed in the setting of traumatic brain injury [2]. Its
predominant site is within the soft tissue surrounding
joints, mostly affecting the hip. Much is yet unknown
concerning the pathophysiology leading to HO, but
several contributing factors have been identified. It is
believed that inappropriate differentiation of pluripo-
tent mesenchymal stem cells into osteoblastic stem
cells plays an important role, which among others is
triggered by local tissue hypoxia [3]. In case of stimula-
tion, these stem cells begin to differentiate into osteo-
blasts with consequent osteoid formation [1]. In this
context, previous studies have demonstrated a clear
correlation between a hypoxic microenvironment and
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HO development [4]. Furthermore, an inducing agent
and a permissive environment seems to be necessary as
described previously by Balboni and colleagues [2].
Urist et al. postulated a small hydrophobic bone mor-
phogenetic protein as a further causative agent [5]. It
was suggested that this protein is liberated from normal
bone in response to venous stasis, inflammation, or in
case of a disease of the connective tissue attachments
to bone [6]. All these conditions are often found in
immobilized patients as well as following trauma. Finally,
Prostaglandin E2 has been shown to influence the differ-
entiation of stem cells as well [7, 8].
As of today, surgical removal is the only treatment
option once HO has occurred. However, postoperative
results are often dissatisfying as high recurrence rates
after excision have been reported and frequently compli-
cate the further course of treatment. Therefore, an ef-
fective prophylactic regimen is of great interest. Current
prophylactic measures generally adhere to one or more
of the following three principles: disrupting the relevant
inductive signaling pathways, altering the relevant osteo-
progenitor cells in the target tissue, or modifying the
environment conducive to heterotopic osteogenesis. The
latter can be influenced by optimizing microcirculation,
which prevents local tissue hypoxia. In this context,
hydroxyethyl starch (HES, Voluven®) has been shown to
reduce local tissue hypoxia by enhancing tissue oxygen
tension and regulating microcirculation in a murine
model [9, 10].
Hoffmann et al. studied the effects of volume support
during microcirculatory disorders in an animal model.
They examined leukocyte-endothelial cell interaction
(LE), functional capillary density (FCD) and macromol-
ecular leakage as indicators of microcirculation using
intravital microscopy. A significantly increased FCD and
less macromolecular leakage was found following the
administration of HES compared to a saline and control
group indicating a positive effect on microcirculation [9].
In an ischemia/reperfusion model in rabbits, one group
was infused with 0.9 % saline and the other group with
HES. Later, muscle biopsies were performed and signifi-
cantly lower myeloperoxidase (MPO) levels were found in
the HES group, demonstrating a positive effect on oxida-
tive stress compared to the saline infusion group [10].
In light of this evidence, the aim of our current study
was to quantitatively assess HO formation following
intravenous administration of HES. We hypothesized
that intravenous administration of HES would lead to
a decrease in HO formation.
Methods
Animal model
Prior to the investigation, approval from the relevant Swiss
authorities was acquired (Kantonale Tierversuchskommission
Zürich, Switzerland, approval number 175/2008), and
experimental animal investigation guidelines of the
European Union (Directive 2010/63/EU) were strictly
adhered to. A pre-existing well-established murine
model was chosen, where HO reliably occurs following
Achilles tendon tenotomy [11–13]. The site of subsequent
HO formation is within the soft tissue surrounding the
tenotomy.
Although the model described does not require a spe-
cific strain or breed of mice, only male specimens were
used. This ensured comparability to other similar inves-
tigations, where only male subjects were used as well.
Cluster of differentiation 1 (CD1) mice were chosen as
they are not genetically modified, bred locally, and finally
handling was facilitated as they are rather large animals.
Identification was carried out by individualized markings
on the tail. All specimens underwent bilateral midpoint
Achilles tendon tenotomy through a posterior approach
(Fig. 1). The skin was subsequently closed using non-
absorbable sutures. Anaesthesia consisted of Isoflurane
(Baxter International Inc., USA), 5–2 % in oxygen at a
flow rate of 400 ml/min via a nose cone, combined with
subcutaneous administration of Buprenorphine (Temgesic,
Reckitt Benckiser, Slough, Great Britain).
Following this procedure, the animals were randomly
assigned to one of two groups: A control group (n = 10)
and a treatment group (n = 10). This sample size was
based on convenience. The control group underwent
Achilles tenotomy only. The treatment group addition-
ally received 200 μl HES (Voluven, Fresenius Kabi, Bad
Homburg, Germany) intravenously by means of a tail
vein injection immediately postoperatively as well as on
the first postoperative day. Intravenous substance appli-
cation in a murine model is best carried out either via
the internal jugular vein by micro-surgically inserting a
catheter, or by means of administration via the tail vein.
Fig. 1 Mouse hind limb Achilles tendon tenotomy
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The latter is easier to perform, but drawbacks include
limited applications, as tail vein thrombosis commonly
occurs after multiple injections. We therefore chose to
administer HES by means of a total of two consecutive
injections. The dose was chosen comparable to a standard
administration in humans (7 ml/kg). This was followed by
10 weeks of cage activity only for both groups.
Acetaminophen syrup was used for postoperative anal-
gesia (Dafalgan 3 %, 200 mg/kg, Bristol-Myers Squibb
SA, New York City, NY, USA), for 1–3 days [14].
All animals were evaluated several times a day postop-
eratively for possible signs of distress, pain and discomfort
such as apathy, shivering as well as reduced chow and
water intake. The findings were recorded on a score-sheet.
If any such signs were noted, treatment with acetamino-
phen was extended and early abortion would have been
considered if any of these signs had persisted. At ten
weeks post-surgery, all mice were euthanized and the
limbs harvested.
Assessment
A micro-computed tomography (CT) scan (SCANCO
Medical Micro CT, Zurich, Switzerland) of all specimens
was performed with a resolution of 30 μm. The generated
images showed a series of 2-dimensional slices through
the specimen (Fig. 2). Using a fixed threshold procedure,
skeletal and ectopic bone were segregated from the back-
ground. Heterotopic bone was then manually identified
and marked. Per definition, HO was identified as any bone
in the soft tissue with a density that was at least equal to
that of spongy skeletal bone. Afterward, each limb was
three-dimensionally reconstructed and the volume of HO
was visualised (Fig. 3). Thereafter, the volume of hetero-
topic bone was calculated using the quantitative bone
analysis software provided with the micro-CT system.
Statistical analysis
Statistics were performed in cooperation with the division
of biostatistics at the Institute for Social and Preventive
Medicine of the University of Zurich, Switzerland. Data
were given as heterotopic bone volume in mm3. The
analysis was performed with SPSS (Version 2.0, IBM,
Chicago, IL, USA). Bone volume was examined using
descriptive statistics (ANOVA) and as data was not
normally distributed, differences between the groups
were identified using the Wilcoxon rank sum test. Cat-
egorical data was assessed with the Fisher’s exact test.
The level of significance was set at p < 0.05.
Results
The first two specimens died perioperatively which was
attributed to anaesthesiologic reasons. All subsequent
procedures could be carried out without complications.
All of the remaining 18 animals survived and were ran-
domly allocated to either the control or treatment
group. No further severe adverse events were recorded.
Acetaminophen use and postoperative ambulation were
comparable in both groups. All limbs were harvested at
ten weeks postoperatively and scanned to assess HO
formation.
Overall, HO occurred in 32/36 (88.9 %) limbs, while
no HO was observed in 4/36 (11.1 %) limbs. It occurred
in 17 of 18 (94.4 %) specimens in the control group and
in 15 of 18 (83.3 %) specimens in the treatment group.
Fig. 2 Micro CT 2D image of mouse hind limb with HO Fig. 3 Micro CT 3D reconstruction of mouse hind limb with HO
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This difference was, however, not significant (p = 0.603).
In both groups alike, HO formation occurred in several
different independent small areas and did not typically
consist of one single continuous mass. There was no
statistical difference between both groups regarding the
number of islets of HO that formed. There was a highly
significant difference in the cumulative volume of HO
between both groups with decreased HO volume in the
treatment group compared to the control group (p =
0.005, Fig. 4). In the treatment group, the mean cumula-
tive HO volume was 0.271 mm3 (range, 0–8.27 mm3,
SD 0.269 mm3, Fig. 5) compared to 2.276 mm3 in the
control group (range, 0–17.0 mm3, standard deviation
(SD) 4.047 mm3). Following administration of HES, a
subsequent substantial reduction of mean HO bone
volume of 88 % was therefore recorded.
Discussion
Prevention of heterotopic ossification is of great clinical
interest as it is a complication commonly seen following
trauma, orthopaedic surgery and particularly joint
arthroplasty [15]. It may lead to pain and joint contrac-
tures. Prevention and treatment of HO is based on three
principles: (1) disrupting the relevant inductive signal-
ing pathways, (2) altering the relevant osteoprogenitor
cells in the target tissue and (3) modifying the environ-
ment conducive for heterotopic osteogenesis [2, 3].
NSAIDs and radiation therapy are currently considered
the gold standard in HO prevention [16, 17]. They act
by modifying the microenvironment as they reduce the
associated inflammatory process involved in HO forma-
tion. Despite their efficacy, complete prevention of HO
often cannot be ensured. Furthermore, use of NSAIDs
is controversial due to potentially deleterious gastro-
intestinal side effects, impaired fracture healing and
possibly decreased implant ingrowth [18–20]. These
are two particularly unfavorable effects in a trauma
setting or following joint arthroplasty.
To date, none of these undesirable effects have been
documented following administration of HES. Further-
more, HES is already in use today for volume resuscitation
in a trauma setting to reduce the need for allogenic blood
transfusion and improve rheology by decreasing the blood
viscosity [21, 22]. Previous studies demonstrated reduced
local tissue hypoxia following the administration of HES
by enhancement of tissue oxygen tension and regulation
of microcirculation in animal models [9, 10].
A hypoxic microenvironment appears to be an import-
ant contributing factor in the formation of ectopic bone.
In this context, Olmsted et al. have studied the micro-
environment surrounding the site where HO develops
and reported that brown adipocytes started accumulating
in this area through generation of hypoxic stress within
the target tissue, a necessity for the differentiation of stem
cells into chondrocytes, subsequently leading to hetero-
topic bone formation [23].
Fig. 4 Box-Whisker plot showing HO volume for both groups. The natural logarithm of data is presented due to the non-normal distribution
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A key factor in differentiation of mesenchymal stem
cells to chondrocyte cells is HIF-1 alpha [24]. It directly
influences chondrocyte-specific gene expression and sub-
sequent differentiation of mesenchymal stem cells to
chondrocytes [25].
With pre-existing evidence indicating a beneficial ef-
fect of HES on local soft tissue microenvironment and
microcirculation, we set out to investigate the clinical
effect of HES on HO formation in a murine model. The
model used has been shown to consistently produce
islets of ectopic bone in the surrounding soft tissue
following a midpoint Achilles tendon tenotomy [11].
Mouse hind limbs were harvested ten weeks postop-
eratively and formation of HO was assessed with use
of Micro CT. Contrary to the original publication of
McClure and colleagues, where HO was reported in
100 % of the tenotomized specimens, we found an overall
occurrence of ectopic bone following this procedure in
88.9 % of all limbs (n = 32/36), while no HO was observed
in 11.1 % (n = 4/36). It occurred in all but one of the speci-
mens in the control group (94.4 %, n = 17/18), while three
specimens in the treatment group (16.7 %, n = 3/18)
showed no signs of HO bone formation at all. The
complete absence of HO in three cases in the treatment
group was desired, but due to the small sample size, this
difference may have not been statistically significant (p =
0.603). A highly significant difference in mean ectopic
bone volume could be found however, with a mean HO
bone volume of 2.276 mm3 in the control group com-
pared to 0.271 mm3 in the treatment group. A remarkable
reduction of mean volume of ectopic bone formation of
88 % was therefore found following the delivery of HES.
Beside other previously investigated experimental sub-
stances influencing the formation of ectopic bone forma-
tion, such as Echinomycin or Imatinib, the great advantage
of HES is the substantially better side effect profile with a
low incidence of undesirable effects [12, 13, 26]. HES is
already implemented in daily use for volume resuscitation
in a trauma or surgical setting involving hemorrhage or
shock.
Although the volume of HO formation could be re-
duced, it was not possible to completely prevent ectopic
bone formation in most cases (83.3 % n = 15/18). We
assume that multiple additional involved signaling path-
ways, which were not influenced by HES, may account
in part for this. Therefore, application of just one sub-
stance seems unlikely to completely prevent ectopic
bone formation.
Further studies are necessary to evaluate a possible com-
bination of administered substances for a more effective
prevention of HO, possibly by influencing other contribut-
ing factors such as increased release of Prostaglandin E2,
hypercalcemia, changes in symptomatic nerve activity and
the disequilibrium of parathyroid hormone and calcitonin
[3, 7, 27].
To our knowledge, this is the first study to describe
the clinical effect of HES on HO formation in a standard-
ized model. However, this investigation has its limitations.
As our study utilized a murine model, the applicability of
our results in a clinical setting has yet to be investigated.
Further, the small sample size of ten mice per group and
nine mice per group at final follow-up may be criticized. As
this work can be regarded as a pilot study, the sample size
was chosen as small as possible. However, we believe that
this does not substantially influence our results as we
were able to demonstrate a statistically significant dif-
ference in HO formation between the groups despite
the small sample size. Although previous investigations
have brought up substantial evidence in order to explain
the above mentioned involved signaling pathways, which
are involved in HO formation, the exact mechanism by
which HES led to a reduction of HO formation in our
current study remains speculative and has yet to be ex-
plored. The present study merely evaluated the clinical ef-
fect of HES. Furthermore, a third study arm would be
desirable with administration of intravenous saline as a
control as well as a comparison with current standard
treatment with a non-steroidal anti-inflammatory drug,
such as Indomethacin, in order to better understand the
potential of HES to reduce HO formation.
Finally, it is known that current preventive measures
for HO may interfere with physiological fracture healing
as well as implant ingrowth. The effects of HES on frac-
ture healing as well as implant ingrowth have yet to be
investigated as well.
Beside these limitations, our results are the first to dem-
onstrate a clinical effect of intravenous perioperative ad-
ministration of HES on HO formation with a relevant
decrease of ectopic bone. Finally, we are aware that this
novel approach is merely the groundwork in an area war-
ranting further research to assess the potential of HES in
patients. These promising preliminary results, however,
may lead to a more effective prevention of HO in the future
by a simple addition to current prophylactic measures.
Fig. 5 Mean and median bone volume (mm3) for control and
treatment group
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Conclusions
Formation of heterotopic bone is a frequent complication
following trauma, burns and orthopedic surgery. Treatment
is often challenging, as high recurrence rates following surgi-
cal excision have been reported. Current prophylactic mea-
sures have proven efficacy, but may not always completely
prevent HO from occurring. For this reason, we searched
for a novel approach to further improve prevention of HO.
We found a substantial decrease in heterotopic bone
formation following perioperative short-term administra-
tion of hydroxyethyl starch in a standardized murine
model. This work represents a preliminary study as the
mechanism of action of HES, as well as applicability in
humans, have yet to be investigated. However, this sim-
ple addition to current prophylactic measures could lead
to a more effective prevention of HO in the future.
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